Charalampos Gousis
Consultant medical oncologist (breast cancer)
Biography
Charalampos (Harris) Gousis is a consultant medical oncologist specialising in breast cancer, with clinics at Guy's Cancer Centre and Queen Elizabeth Hospital. He treats patients with early and advanced breast cancer using chemotherapy, hormone therapy, immunotherapy and targeted therapies.
After qualifying as a doctor in 2012, he trained in Greece, the USA and the UK before joining Guy's and St Thomas' in 2018. He was appointed as a consultant in 2023.
He is also the Operational and Governance Clinical Lead for Oncology at Lewisham and Greenwich NHS Trust and holds a Doctor of Medicine (Research) in Cancer Studies from King's College London.
Education and training
- Doctor of Medicine (Research) in cancer studies, School of Cancer and Pharmaceutical Sciences, King's College London, 2023 to 2026
- Certificate of completion of training in medical oncology, Greece, 2023
- Senior clinical fellow and specialty trainee in medical oncology, Guy's and St Thomas' NHS Foundation Trust, London, 2018 to 2023
- Internal medicine training, General Hospital of Kavala, Greece, including a haemato-oncology rotation at AHEPA University Hospital, Thessaloniki, 2015 to 2017
- Junior oncology fellow, The Christie NHS Foundation Trust, Manchester, 2015
- Medical oncology training, Theagenion Cancer Hospital, Thessaloniki, Greece, 2014 to 2015
- Research fellow, Children's Hospital of Philadelphia, University of Pennsylvania, USA, 2012 to 2013
- Medical Degree (MD), Aristotle University of Thessaloniki, Greece, 2012, including clinical rotations at University Hospital Essen, Germany
Research interests
- Real-world outcomes of new breast cancer treatments
- Reducing inequalities in cancer care
- Lung cancer in people who have never smoked and the role of air pollution (MD research thesis)
Awards
- Pan-London Cancer Research Fellowship, Royal Marsden Partners, 2021 to 2022
- Commendation for exceptional clinical practice as a military physician, Greek Special Forces, 2014
Contact
Email: [email protected]
Specialist interests
- Early breast cancer, including treatment before and after surgery
- Advanced (secondary or metastatic) breast cancer
- Hormone receptor-positive breast cancer, including CDK4/6 inhibitors and other targeted treatments
- HER2-positive breast cancer, including antibody-drug conjugates
- Triple-negative breast cancer, including immunotherapy
Last updated: October 2026